Bio-Rad Laboratories
BIO · Life Sciences Tools & Services
$369.95
1.8%Charles River Laboratories
CRL · Life Sciences Tools & Services
$345.37
1.7%The short version
- Charles River Laboratories is the larger business, with $4.0B of revenue in fiscal 2025 against $2.6B for Bio-Rad Laboratories, about 1.6 times as much.
- Bio-Rad Laboratories grew revenue faster (0.7%, against −0.9%).
- Bio-Rad Laboratories kept more of each dollar of sales as operating profit (1.8% operating margin, against 0.6% operating margin).
- Bio-Rad Laboratories turned more of its sales into free cash flow (14.5% FCF margin, against 12.9% FCF margin).
| Latest fiscal year | BIO · FY25 | CRL · FY25 |
|---|---|---|
| Size | ||
| Market cap | $9.9B | $16.6B |
| Revenue | $2.6B | $4.0B |
| Free cash flow | $375M | $518M |
| Net income | $760M | −$144M |
| Growth | ||
| Revenue growth | 0.7% | −0.9% |
| 5-year growth | 0.3% | 6.6% |
| Share count change | −3.3% | −4.0% |
| Profitability | ||
| Gross margin | 51.9% | — |
| Operating margin | 1.8% | 0.6% |
| Net margin | 29.4% | −3.6% |
| FCF margin | 14.5% | 12.9% |
| Return on capital | 0.5% | 0.4% |
| Return on equity | 10.8% | −4.4% |
| Balance sheet | ||
| Net debt | −$329M | $1.9B |
| Net debt / EBITDA | −1.6x | 4.5x |
| Dividends and buybacks | $296M | $361M |
| Valuation & quality | ||
| P/E | 46.3x | — |
| Piotroski F-score | 5 | 4 |
FY16
BIO $2.1B
CRL $1.7B
FY17
BIO $2.2B
CRL $1.9B
FY18
BIO $2.3B
CRL $2.3B
FY19
BIO $2.3B
CRL $2.6B
FY20
BIO $2.5B
CRL $2.9B
FY21
BIO $2.9B
CRL $3.5B
FY22
BIO $2.8B
CRL $4.0B
FY23
BIO $2.7B
CRL $4.1B
FY24
BIO $2.6B
CRL $4.1B
FY25
BIO $2.6B
CRL $4.0B
BIO
CRL
FY16
BIO 2.7%
CRL 14.1%
FY17
BIO 5.5%
CRL 15.5%
FY18
BIO −4.5%
CRL 14.6%
FY19
BIO 9.9%
CRL 13.4%
FY20
BIO 16.6%
CRL 14.8%
FY21
BIO 17.1%
CRL 16.7%
FY22
BIO 17.2%
CRL 16.4%
FY23
BIO 12.7%
CRL 15.0%
FY24
BIO 10.5%
CRL 5.6%
FY25
BIO 1.8%
CRL 0.6%
BIO
CRL
FY16
BIO $74.6M
CRL $262M
FY17
BIO −$7.2M
CRL $236M
FY18
BIO $156M
CRL $301M
FY19
BIO $359M
CRL $340M
FY20
BIO $476M
CRL $380M
FY21
BIO $536M
CRL $532M
FY22
BIO $81.6M
CRL $295M
FY23
BIO $218M
CRL $365M
FY24
BIO $290M
CRL $502M
FY25
BIO $375M
CRL $518M
BIO
CRL
FY16
BIO 1.6%
CRL 10.1%
FY17
BIO 5.0%
CRL 7.5%
FY18
BIO −2.4%
CRL 11.4%
FY19
BIO 4.3%
CRL 9.8%
FY20
BIO 4.8%
CRL 9.9%
FY21
BIO 3.6%
CRL 11.1%
FY22
BIO 3.5%
CRL 9.9%
FY23
BIO 3.1%
CRL 8.9%
FY24
BIO 2.9%
CRL 2.0%
FY25
BIO 0.5%
CRL 0.4%
BIO
CRL
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.